Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466189 | 1.00 | EDNRA (0.72) | EDNRAEDNRB | |
| SCHEMBL5036498 | 0.92 | EDNRA (0.76) | EDNRAEDNRB | |
| SCHEMBL6960195 | 0.92 | EDNRA (0.66) | EDNRAEDNRB | |
| SCHEMBL6585231 | 0.91 | EDNRA (0.73) | EDNRAEDNRB | |
| SCHEMBL6971499 | 0.90 | EDNRA (0.61) | EDNRAEDNRB | |
| SCHEMBL6966755 | 0.89 | EDNRA (0.74) | EDNRAEDNRB | |
| SCHEMBL6961606 | 0.89 | EDNRA (0.66) | EDNRAEDNRB | |
| SCHEMBL6960823 | 0.88 | EDNRA (0.67) | EDNRAEDNRB | |
| SCHEMBL25637066 | 0.88 | EDNRA (0.84) | EDNRAEDNRB | |
| SCHEMBL6963021 | 0.87 | EDNRA (0.64) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0897914-B1 | Process for the preparation of 2,5-disubstitued pyridines | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | claimed |
| EP-0799209-B1 | SULFONAMIDES | HOFFMANN LA ROCHE (CH) | 2003-08-06 | — | — | EP | claimed |
| US-6080866-A | A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2000-06-27 | — | — | US | claimed |
| US-6004965-A | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-12-21 | — | — | US | claimed |
| EP-0897914-A1 | Process for the preparation of 2,5-disubstitued pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-24 | — | — | EP | claimed |
| EP-0799209-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | claimed |
| WO-1996019459-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | claimed |
| EP-4721742-A2 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Idorsia Pharmaceuticals Ltd (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4582086-A2 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Idorsia Pharmaceuticals Ltd (CH) | 2025-07-09 | — | — | EP | disclosed |
| US-20250051308-A1 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-02-13 | — | — | US | disclosed |
| WO-2023111299-A1 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023111299-A1 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | WO | disclosed |
| EP-0897914-B1 | Process for the preparation of 2,5-disubstitued pyridines | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | disclosed |
| EP-0799209-B1 | SULFONAMIDES | HOFFMANN LA ROCHE (CH) | 2003-08-06 | — | — | EP | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6080866-A | A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2000-06-27 | — | — | US | disclosed |
| US-6004965-A | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0897914-A1 | Process for the preparation of 2,5-disubstitued pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-24 | — | — | EP | disclosed |
| EP-0799209-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019459-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051308-A1 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SSTR5, SSTR3, TACR1 | EDNRA 203/4885EDNRB 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.